Experimental Drug BNC210 Shows Early Promise in PTSD Treatment
Summary Bionomics Limited’s experimental drug BNC210 has shown early promise in treating PTSD, reducing symptom severity in a Phase IIb trial. The study revealed modest improvements in symptoms after 12 … Read More